New routes in frontotemporal dementia drug discovery

References

• Perry DC, Miller BL. Frontotemporal dementia. Semin Neurol. 2013 Sep;33(4):336–341.
   PubMed Web of Science ®Google Scholar
• Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013 Apr;25(2):130–137.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011 Sep;134(Pt 9):2456–2477.
   PubMed Web of Science ®Google Scholar
• Leger GC, Johnson N. A review on primary progressive aphasia. Neuropsychiatr Dis Treat. 2007 Dec;3(6):745–752.
   PubMedGoogle Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496–503.
   PubMed Web of Science ®Google Scholar
• Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996 Nov;47(5):1184–1189.
   PubMed Web of Science ®Google Scholar
• Achi EY, Rudnicki SA. ALS and frontotemporal dysfunction: a review. Neurol Res Int. 2012;2012:806306.
   PubMedGoogle Scholar
• Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013 Aug 7;79(3):416–438.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Kapogiannis D, Huey ED, et al. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 2011 May;8(3):273–294.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong CX, et al. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010 Dec;7(8):656–664.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006 Oct 6;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Nolan M, Talbot K, Ansorge O. Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathol Commun. 2016 Sep 6;4(1):99.
   PubMed Web of Science ®Google Scholar
• Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009 Nov;132(Pt 11):2922–2931.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M, Crowther RA, et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4113–4118.
   PubMed Web of Science ®Google Scholar
• Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006 Aug 24;442(7105):916–919.
   PubMed Web of Science ®Google Scholar
• Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006 Aug 24;442(7105):920–924.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245–256.
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257–268.
   PubMed Web of Science ®Google Scholar
• Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004 Apr;36(4):377–381.
   PubMed Web of Science ®Google Scholar
• Momeni P, Rogaeva E, Van Deerlin V, et al. Genetic variability in CHMP2B and frontotemporal dementia. Neurodegener Dis. 2006;3(3):129–133.
   PubMed Web of Science ®Google Scholar
• Synofzik M, Maetzler W, Grehl T, et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol Aging. 2012 Dec;33(12):2949e13–7.
   Web of Science ®Google Scholar
• Williams KL, Topp S, Yang S, et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016 Apr;15(7):11253.
   Web of Science ®Google Scholar
• Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5ʹ-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998 Jun 18;393(6686):702–705.
   PubMed Web of Science ®Google Scholar
• Drechsel DN, Hyman AA, Cobb MH, et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992 Oct;3(10):1141–1154.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989 Oct;3(4):519–526.
   PubMed Web of Science ®Google Scholar
• Liu F, Gong CX. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener. 2008 Jul 10;3:8.
   PubMed Web of Science ®Google Scholar
• Lu M, Kosik KS. Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell. 2001 Jan;12(1):171–184.
   PubMed Web of Science ®Google Scholar
• Biernat J, Gustke N, Drewes G, et al. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993 Jul;11(1):153–163.
   PubMed Web of Science ®Google Scholar
• Kuret J, Chirita CN, Congdon EE, et al. Pathways of tau fibrillization. Biochim Biophys Acta. 2005 Jan 3;1739(2–3):167–178.
   PubMed Web of Science ®Google Scholar
• Min SW, Chen X, Tracy TE, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015 Oct;21(10):1154–1162.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016 Jan;17(1):5–21.
   PubMed Web of Science ®Google Scholar
• Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013 Jun;12(6):609–622.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016 Aug;138(Suppl 1):54–70.
   PubMed Web of Science ®Google Scholar
• Shiarli AM, Jennings R, Shi J, et al. Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer’s disease. Neuropathol Appl Neurobiol. 2006 Aug;32(4):374–387.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011 Dec;24(6):542–549.
   PubMed Web of Science ®Google Scholar
• Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta. 2005 Jan 3;1739(2–3):240–250.
   PubMed Web of Science ®Google Scholar
• Alonso A, Zaidi T, Novak M, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6923–6928.
   PubMed Web of Science ®Google Scholar
• Alonso Adel C, Mederlyova A, Novak M, et al. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem. 2004 Aug 13;279(33):34873–34881.
   PubMed Web of Science ®Google Scholar
• Goedert M, Satumtira S, Jakes R, et al. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J Neurochem. 2000 Nov;75(5):2155–2162.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213–11218.
   PubMed Web of Science ®Google Scholar
• Crowe A, James MJ, Lee VM, et al. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem. 2013 Apr 19;288(16):11024–11037.
   PubMed Web of Science ®Google Scholar
• Medina DX, Caccamo A, Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011 Mar;21(2):140–149.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 Dec 10;388(10062):2873–2884.
   PubMed Web of Science ®Google Scholar
• Hochgrafe K, Sydow A, Matenia D, et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun. 2015 May;10(3):25.
   Web of Science ®Google Scholar
• Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2002;2(2):131–150.
   PubMed Web of Science ®Google Scholar
• Makani V, Zhang B, Han H, et al. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathol Commun. 2016 Sep 29;4(1):106.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676–685.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014 Apr;29(4):470–478.
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000 Aug;6(8):916–919.
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850–8855.
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis. 2008 Oct;15(2):157–168.
   PubMed Web of Science ®Google Scholar
• Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol. 2009 Jun;21(3):359–363.
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010 Dec 8;30(49):16559–16566.
   PubMed Web of Science ®Google Scholar
• Chai X, Wu S, Murray TK, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011 Sep 30;286(39):34457–34467.
   PubMed Web of Science ®Google Scholar
• Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012 May;9(4):397–405.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. Biomed Res Int. 2016;2016:1–15.
   Web of Science ®Google Scholar
• Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012 Jan 20;11(2):125–140.
   PubMed Web of Science ®Google Scholar
• Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002 Mar;1(5):347–355.
   PubMed Web of Science ®Google Scholar
• Kalbfuss B, Mabon SA, Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem. 2001 Nov 16;276(46):42986–42993.
   PubMed Web of Science ®Google Scholar
• Sud R, Geller ET, Schellenberg GD. Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol Ther Nucleic Acids. 2014 Jul;29(3):e180.
   Google Scholar
• Budini M, Romano V, Quadri Z, et al. TDP-43 loss of cellular function through aggregation requires additional structural determinants beyond its C-terminal Q/N prion-like domain. Hum Mol Genet. 2015 Jan 1;24(1):9–20.
   PubMed Web of Science ®Google Scholar
• Wu LS, Cheng WC, Hou SC, et al. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis. 2010 Jan;48(1):56–62.
   PubMed Web of Science ®Google Scholar
• Iguchi Y, Katsuno M, Niwa J, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013 May;136(Pt 5):1371–1382.
   PubMed Web of Science ®Google Scholar
• Cragnaz L, Klima R, De Conti L, et al. An age-related reduction of brain TBPH/TDP-43 levels precedes the onset of locomotion defects in a Drosophila ALS model. Neuroscience. 2015 Dec 17;311:415–421.
   PubMed Web of Science ®Google Scholar
• Langellotti S, Romano V, Romano G, et al. A novel Drosophila model of TDP-43 proteinopathies: N-terminal sequences combined with the Q/N domain induce protein functional loss and locomotion defects. Dis Model Mech. 2016 Jun 1;9(6):659–669.
   PubMed Web of Science ®Google Scholar
• Ayala YM, De Conti L, Avendano-Vazquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. Embo J. 2011 Jan 19;30(2):277–288.
   PubMed Web of Science ®Google Scholar
• Buratti E, Baralle FE. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci. 2012 Jun;37(6):237–247.
   PubMed Web of Science ®Google Scholar
• Alami NH, Smith RB, Carrasco MA, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014 Feb 5;81(3):536–543.
   PubMed Web of Science ®Google Scholar
• Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006 Oct 15;15(20):2988–3001.
   PubMed Web of Science ®Google Scholar
• Gijselinck I, Van Broeckhoven C, Cruts M. Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum Mutat. 2008 Dec;29(12):1373–1386.
   PubMed Web of Science ®Google Scholar
• Van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 2008 Oct;7(10):965–974.
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Xu YF, Dickey CA, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007 Sep 26;27(39):10530–10534.
   PubMed Web of Science ®Google Scholar
• Dormann D, Capell A, Carlson AM, et al. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem. 2009 Aug;110(3):1082–1094.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics. 2007 Nov;8(4):237–248.
   PubMed Web of Science ®Google Scholar
• Van Der Zee J, Gijselinck I, Dillen L, et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013 Feb;34(2):363–373.
   PubMed Web of Science ®Google Scholar
• Tang BL. C9orf72’s interaction with rab GTPases-modulation of membrane traffic and autophagy. Front Cell Neurosci. 2016;10:228.
   PubMed Web of Science ®Google Scholar
• Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet. 2014 Jul 1;23(13):3579–3595.
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4530–9.
   PubMed Web of Science ®Google Scholar
• Lee YB, Chen HJ, Peres JN, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013 Dec 12;5(5):1178–1186.
   PubMed Web of Science ®Google Scholar
• Cooper-Knock J, Walsh MJ, Higginbottom A, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 2014 Jul;137(Pt 7):2040–2051.
   PubMed Web of Science ®Google Scholar
• Cleary JD, Ranum LP. Repeat-associated non-ATG (RAN) translation in neurological disease. Hum Mol Genet. 2013 Oct 15;22(R1):R45–51.
   PubMed Web of Science ®Google Scholar
• Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013 Feb 20;77(4):639–646.
   PubMed Web of Science ®Google Scholar
• Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013 Mar 15;339(6125):1335–1338.
   PubMed Web of Science ®Google Scholar
• Gitcho MA, Strider J, Carter D, et al. VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. J Biol Chem. 2009 May 1;284(18):12384–12398.
   PubMed Web of Science ®Google Scholar
• Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet. 2007 Nov;72(5):420–426.
   PubMed Web of Science ®Google Scholar
• Rabinovich E, Kerem A, Frohlich KU, et al. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol Cell Biol. 2002 Jan;22(2):626–634.
   PubMed Web of Science ®Google Scholar
• Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol. 2001 Aug;3(8):740–744.
   PubMed Web of Science ®Google Scholar
• Wang Y, Meriin AB, Zaarur N, et al. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. Faseb J. 2009 Feb;23(2):451–463.
   PubMed Web of Science ®Google Scholar
• Yao TP. The role of ubiquitin in autophagy-dependent protein aggregate processing. Genes Cancer. 2010 Jul 1;01(7):779–786.
   Google Scholar
• Bartolome F, Wu HC, Burchell VS, et al. Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron. 2013 Apr 10;78(1):57–64.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010 Oct;9(10):995–1007.
   PubMed Web of Science ®Google Scholar
• Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011 Aug 21;477(7363):211–215.
   PubMed Web of Science ®Google Scholar
• Hjerpe R, Bett JS, Keuss MJ, et al. UBQLN2 mediates autophagy-independent protein aggregate clearance by the proteasome. Cell. 2016 Aug 11;166(4):935–949.
   PubMed Web of Science ®Google Scholar
• Liu R, Yang G, Nonaka T, et al. Reducing TDP-43 aggregation does not prevent its cytotoxicity. Acta Neuropathol Commun. 2013 Aug 9;1:49.
   PubMedGoogle Scholar
• Xu YF, Gendron TF, Zhang YJ, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010 Aug 11;30(32):10851–10859.
   PubMed Web of Science ®Google Scholar
• Winton MJ, Igaz LM, Wong MM, et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008 May 9;283(19):13302–13309.
   PubMed Web of Science ®Google Scholar
• Budini M, Buratti E, Stuani C, et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem. 2012 Mar 2;287(10):7512–7525.
   PubMed Web of Science ®Google Scholar
• Prpar Mihevc S, Baralle M, Buratti E, et al. TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci Rep. 2016 Sep 26;6:33996.
   PubMed Web of Science ®Google Scholar
• Boyd JD, Lee-Armandt JP, Feiler MS, et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen. 2014 Jan;19(1):44–56.
   PubMedGoogle Scholar
• Barmada SJ, Serio A, Arjun A, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014 Aug;10(8):677–685.
   PubMed Web of Science ®Google Scholar
• Xia Q, Wang H, Hao Z, et al. TDP-43 loss of function increases TFEB activity and blocks autophagosome-lysosome fusion. Embo J. 2016 Jan 18;35(2):121–142.
   PubMed Web of Science ®Google Scholar
• Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010 Sep 9;467(7312):179–184.
   PubMed Web of Science ®Google Scholar
• Crippa V, Sau D, Rusmini P, et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum Mol Genet. 2010 Sep 1;19(17):3440–3456.
   PubMed Web of Science ®Google Scholar
• Gregory JM, Barros TP, Meehan S, et al. The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila. PLoS One. 2012;7(2):e31899.
   PubMed Web of Science ®Google Scholar
• Jackrel ME, DeSantis ME, Martinez BA, et al. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell. 2014 Jan 16;156(1–2):170–182.
   PubMed Web of Science ®Google Scholar
• Riboldi G, Zanetta C, Ranieri M, et al. Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases. Mol Neurobiol. 2014 Dec;50(3):721–732.
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013 Oct 16;80(2):415–428.
   PubMed Web of Science ®Google Scholar
• Sareen D, O’Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013 Oct 23;5(208):208ra149.
   PubMed Web of Science ®Google Scholar
• Davidson YS, Barker H, Robinson AC, et al. Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 2014 Jun 20;2:70.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Arzberger T, Kremmer E, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013 Dec;126(6):859–879.
   PubMed Web of Science ®Google Scholar
• Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001 Dec 28;107(7):823–826.
   PubMed Web of Science ®Google Scholar
• Peters OM, Cabrera GT, Tran H, et al. Human C9ORF72 hexanucleotide expansion reproduces RNA Foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015 Dec 2;88(5):902–909.
   PubMed Web of Science ®Google Scholar
• Liu CR, Chang CR, Chern Y, et al. Spt4 is selectively required for transcription of extended trinucleotide repeats. Cell. 2012 Feb 17;148(4):690–701.
   PubMed Web of Science ®Google Scholar
• Kramer NJ, Carlomagno Y, Zhang YJ, et al. Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science. 2016 Aug 12;353(6300):708–712.
   PubMed Web of Science ®Google Scholar
• Cheng HM, Chern Y, Chen IH, et al. Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown. PLoS Genet. 2015 Mar;11(3):e1005043.
   PubMed Web of Science ®Google Scholar
• Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008 Dec 1;17(23):3631–3642.
   PubMed Web of Science ®Google Scholar
• Jiao J, Herl LD, Farese RV, et al. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS One. 2010 May 10;5(5):e10551.
   PubMed Web of Science ®Google Scholar
• Wang WX, Wilfred BR, Madathil SK, et al. miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol. 2010 Jul;177(1):334–345.
   PubMed Web of Science ®Google Scholar
• Capell A, Liebscher S, Fellerer K, et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci. 2011 Feb 2;31(5):1885–1894.
   PubMed Web of Science ®Google Scholar
• Cenik B, Sephton CF, Dewey CM, et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011 May 6;286(18):16101–16108.
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Llewellyn KJ, Nguyen C, et al. Targeted excision of VCP R155H mutation by Cre-LoxP technology as a promising therapeutic strategy for valosin-containing protein disease. Hum Gene Ther Methods. 2015 Feb;26(1):13–24.
   PubMed Web of Science ®Google Scholar
• Picher-Martel V, Valdmanis PN, Gould PV, et al. From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun. 2016 Jul 11;4(1):70.
   PubMed Web of Science ®Google Scholar
• Nishimura AL, Shum C, Scotter EL, et al. Allele-specific knockdown of ALS-associated mutant TDP-43 in neural stem cells derived from induced pluripotent stem cells. PLoS One. 2014;9(3):e91269.
   PubMed Web of Science ®Google Scholar
• Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol. 2014 Jun;10(6):337–348.
   PubMed Web of Science ®Google Scholar
• Miguel L, Avequin T, Delarue M, et al. Accumulation of insoluble forms of FUS protein correlates with toxicity in Drosophila. Neurobiol Aging. 2012 May;33(5):1008e1–15.
   Web of Science ®Google Scholar
• Sharma A, Lyashchenko AK, Lu L, et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016 Feb;04(7):10465.
   Web of Science ®Google Scholar
• Huey ED, Ferrari R, Moreno JH, et al. FUS and TDP43 genetic variability in FTD and CBS. Neurobiol Aging. 2012 May;33(5):1016e9–17.
   Web of Science ®Google Scholar
• Fujii S, Takanashi K, Kitajo K, et al. Treatment with a global methyltransferase inhibitor induces the intranuclear aggregation of ALS-linked FUS mutant in vitro. Neurochem Res. 2016 Apr;41(4):826–835.
   PubMed Web of Science ®Google Scholar
• Isaacs AM, Johannsen P, Holm I, et al. Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res. 2011 May;8(3):246–251.
   PubMed Web of Science ®Google Scholar
• Nielsen TT, Mizielinska S, Hasholt L, et al. Reversal of pathology in CHMP2B-mediated frontotemporal dementia patient cells using RNA interference. J Gene Med. 2012 Aug;14(8):521–529.
   PubMed Web of Science ®Google Scholar
• Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degenerations–progress and challenges. Prog Neurobiol. 2011 Dec;95(4):636–648.
   PubMed Web of Science ®Google Scholar
• Borroni B, Turrone R, Galimberti D, et al. Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. Neurol Sci. 2015 May;36(5):751–757.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Elias N, Koel-Simmelink MJ, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016;2:86–94.
   PubMedGoogle Scholar
• Gendron TF, Chew J, Stankowski JN, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017 Mar 29;9(383).
   PubMed Web of Science ®Google Scholar
• Saint-Aubert L, Lemoine L, Chiotis K, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017 Feb 20;12(1):19.
   PubMed Web of Science ®Google Scholar
• Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol. 2003 Feb;10(2):120–125.
   PubMedGoogle Scholar
• Nurputra DK, Lai PS, Harahap NI, et al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann Hum Genet. 2013 Sep;77(5):435–463.
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014 Jan;75(1):116–126.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Woollacott IO, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016 Sep 27;87(13):1329–1336.
   PubMed Web of Science ®Google Scholar
• Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016 Aug;3(8):623–636.
   PubMed Web of Science ®Google Scholar
• Chew J, Gendron TF, Prudencio M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015 Jun 5;348(6239):1151–1154.
   PubMed Web of Science ®Google Scholar